Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients
- PMID: 1515247
- DOI: 10.1016/0959-8049(92)90515-4
Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients
Abstract
Antiemetic activity of three protracted regimens for the control of cisplatin-evoked delayed emesis was explored. 63 patients were randomly assigned to receive one of three protracted antiemetic schedules over 4 days. Group C patients received dexamethasone 8 mg twice daily on days 2 and 3, then 4 mg twice daily on days 4 and 5; in group B, alizapride 2.5 mg/kg four times daily on days 2-5 plus dexamethasone as in group C was administered; and in group A, metoclopramide 0.5 mg/kg four times daily on days 2-5 plus dexamethasone was given at the same dose-schedule as in groups C and B. Complete protection from delayed vomiting was achieved in 44% of group C, 30% of B and 70% of group A (P = 0.02). Mild side-effects were noted in all three groups. A higher complete protection for delayed emesis was obtained in metoclopramide-dexamethasone-treated patients. Neither of the regimens used in the protection of delayed emesis controlled late nausea.
Similar articles
-
Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.J Clin Oncol. 1997 Jan;15(1):124-30. doi: 10.1200/JCO.1997.15.1.124. J Clin Oncol. 1997. PMID: 8996133 Clinical Trial.
-
Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.Lancet. 1992 Jul 11;340(8811):96-9. Lancet. 1992. PMID: 1352024 Clinical Trial.
-
Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.Indian J Med Res. 2004 Sep;120(3):183-93. Indian J Med Res. 2004. PMID: 15489556 Clinical Trial.
-
[Recent improvements in antiemetic therapy].Tumori. 1997;83(2 Suppl):S3-14. Tumori. 1997. PMID: 9235727 Review. Italian.
-
[Research on antiemetics: an Italian model of success].Tumori. 1998 Jan-Feb;84(1 Suppl):S3-11. Tumori. 1998. PMID: 9617377 Review. Italian.
Cited by
-
Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413.Br J Cancer. 1997;76(1):90-2. doi: 10.1038/bjc.1997.341. Br J Cancer. 1997. PMID: 9218738 Free PMC article. Clinical Trial.
-
Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings.Support Care Cancer. 2007 May;15(5):497-503. doi: 10.1007/s00520-006-0173-z. Epub 2006 Nov 14. Support Care Cancer. 2007. PMID: 17103197
-
Delayed emesis: a dilemma in antiemetic control.Support Care Cancer. 1993 Jul;1(4):182-5. doi: 10.1007/BF00366444. Support Care Cancer. 1993. PMID: 8193879 Review.
-
Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis.Br J Cancer. 1994 Dec;70(6):1161-4. doi: 10.1038/bjc.1994.465. Br J Cancer. 1994. PMID: 7981069 Free PMC article. Clinical Trial.
-
Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.Br J Cancer. 1999 May;80(3-4):412-8. doi: 10.1038/sj.bjc.6690372. Br J Cancer. 1999. PMID: 10408847 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical